Pharmacy benefit manager spread economics: NADAC reference price vs reimbursed price vs plan-paid price across high-volume generics.
The fields present on each record, named exactly as they appear in the data, so a query written against this list will run.
Released under CC BY 4.0. You may use it commercially and redistribute it. Attribution is the only condition.
Couey, V. W. (2026). PBM Spread Pricing 2026. Deep Synthesis. https://doi.org/10.5281/zenodo.20632743
FDA CAERS-derived adverse event reports for dietary supplements over a decade: ingredient category, severity, outcome, year. Modeled estimates.
Brand-name drug patent expirations 2024-2028, generic entry timing, and per-drug savings on substitution.